A qualitative classification signature for post-surgery 5-fluorouracil-based adjuvant chemoradiotherapy in gastric cancer. (February 2021)

• Record Type: Journal Article
• Authors: Li, Meifeng; Chen, Haifeng; He, Jun; Xie, Jiajing; Xia, Jie; Liu, Hui; Shi, Yidan; Guo, Zheng; Yan, Haidan
• Is Part Of: Radiotherapy and oncology. Volume 155(2021)
• Page Start: 65
• Page End: 72
• Publication Date: 2021-02
• Subjects: GC gastric cancer -- 5-FU 5-Fluorouracil -- ACRT adjuvant chemoradiotherapy -- REOs relative expression orderings -- GEO Gene Expression Omnibus -- TCGA The Cancer Genome Atlas -- OS overall survival -- DFS disease free survival -- RFS recurrent free survival -- DEGs differentially expressed genes -- HR hazard ratios -- CI confidence intervals -- FDR false discovery rate; Gastric cancer -- 5-Fluorouracil-based adjuvant chemoradiotherapy -- Classification signature -- Relative expression orderings; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2020.10.011
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: We developed a classification signature to accurately classify GC patients who may benefit from 5-FU-based ACRT. The 34-GPS was not a signature for GCs treated with surgery alone and 5-FU based chemotherapy alone. The signature can be applied in an individual level, which could aid clinicians in tailoring more effective GC treatments. Abstract: Background and purpose: Currently, 5-fluorouracil (5-FU)-based adjuvant chemoradiotherapy (ACRT) is a preferred regimen for post-surgery gastric cancer (GC). However, the survival outcome of 5-FU-based ACRT varies greatly among different GC patients. Thus, it is necessary to classify which patients may benefit from 5-FU-based ACRT. Materials and methods: We collected 577 GC and 84 adjacent normal samples for training and 675 GC samples for validation. Based on the within-sample relative expression orderings (REOs) of gene expression levels, reversal gene pairs were selected, and the pairs correlating with overall survival (OS) of GC patients receiving 5-FU-based ACRT were identified as candidates. Finally, an optimized set of candidate gene pairs was selected as a classification signature in training data and validated in validation data. Results: A signature consisting of 34 gene pairs was identified in training data and validated in three independent datasets. The classified low-risk group had better OS than the classified high-risk group. We also analyzed the recurrent free survival or disease free survival (RFS/DFS) of the validation datasets, and the similar results were shown. Furthermore, although the signature was identified based on the OS of GC patients receiving ACRT, it was not a prognostic signature for patients treated with surgery alone, but may be a potential signature for 5-FU-based chemotherapy alone. Conclusions: The signature can accurately classify GC patients who may benefit from 5-FU-based ACRT, which could aid clinicians in tailoring more effective GC treatments.